Approval · Notice of Compliance 3987 · 1997
TRANSDERM-NITRO: Notice of Compliance 3987
Issued June 18, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3987
- Date
- June 18, 1997
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Therapeutic class
- Antianginal
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TRANSDERM-NITRO | 00584223 | Cancelled Post Market |
| TRANSDERM-NITRO | 00852384 | Cancelled Post Market |
| TRANSDERM-NITRO | 02046156 | Cancelled Post Market |
| TRANSDERM-NITRO | 02046164 | Cancelled Post Market |
Medicinal ingredients
- NITROGLYCERIN 25 MG per PAD
- NITROGLYCERIN 50 MG per PAD
- NITROGLYCERIN 75 MG per PAD
- NITROGLYCERIN 100 MG per PAD